<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report here the 10-year follow-up of 86 patients who underwent allogeneic stem cell transplantation (ASCT) for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received the <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (BAC) preparative regimen which consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi> 16 mg/kg, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> 8 g/m(2) IV, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg IV </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-nine patients (69%) had de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 26 (30%) had <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> (treatment related), and one had a preceding <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> which progressed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> before transplant </plain></SENT>
<SENT sid="3" pm="."><plain>Cytogenetics (80 patients) was classified as good (34%), intermediate (17%), or poor (42%) </plain></SENT>
<SENT sid="4" pm="."><plain>With a median follow-up for survivors of 124 months, the 10-year Kaplan-Meier estimates for overall survival (OS) was 43% (95% confidence interval [CI]: 31-53%) </plain></SENT>
<SENT sid="5" pm="."><plain>Cumulative nonrelapse mortality (NRM) and relapse was 43% (95% CI: 32-54%) and 19% (95% CI: 11-27%), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>No patient relapsed after 2 years </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 10-year relapse-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>), relapse, and NRM was 36%, 36%, and 27%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Younger age (P = 0.05), human leukocyte antigen (HLA) match (P = 0.002), good risk cytogenetics (P = 0.008), and having a related donor (P = 0.03) significantly improved overall and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> in the multivariable analysis </plain></SENT>
<SENT sid="9" pm="."><plain>The long-term follow-up of patients receiving the BAC regimen with ASCT in this study indicated durable relapse-free and OS with acceptable toxicity in this group of patients with high-risk features </plain></SENT>
</text></document>